Developer docs
API playgroundTry for free, no card

Search company profiles

OpenBiome

Full company profile

uuid0002ppd

Namestring
OpenBiome
Legal namestring
The OpenBiome Foundation
Websiteurl
openbiome.org
Company typeenum
Private
Founded yearint
2012
Descriptiontext

OpenBiome Foundation is a U.S. nonprofit organization, originally founded in 2012 as an MIT spinout, that operated the first public stool bank in the United States delivering investigational fecal microbiota transplantation (FMT) treatments for Clostridioides difficile (C. diff) infections. Over more than a decade it built standardized, cryopreserved FMT preparations and high-dose protocols for severe/fulminant disease, ultimately delivering 72,000+ investigational treatments to 1,300+ hospitals and clinics and contributing to the field that produced the first two FDA-approved live biotherapeutic drugs for C. diff. Following the FDA's decision to end enforcement discretion for stool banks, OpenBiome ceased direct FMT distribution in 2025 and reorganized as the OpenBiome Foundation on July 16, 2025.

Under the Foundation model, the organization no longer sells or distributes FMT products commercially. Its current offerings center on (1) the OpenBiome Biorepository—an open-access repository of stool samples and associated clinical data, (2) a targeted Grant Making Program funding pioneering microbiome research globally, (3) Field Building programs including white papers, clinical webinars, and the OpenDialog newsletter, and (4) advocacy for sound health policy and hospital-based FMT programs. Core technology assets include the proprietary donor screening and stool-banking protocols developed over the operational period and an IND-track manufacturing relationship with the University of Minnesota Microbiota Therapeutics Program (Dr. Alexander Khoruts).

The revenue model is foundation/grant-based: OpenBiome is funded through donations, grants, and charitable contributions rather than commercial sales, with disclosed historical capital limited to a $100K–$125K Y Combinator investment (Aug 2020) and small grants from the Draper Richards Kaplan Foundation (2022) and WPSS.bio (2020). Its go-to-market is community-led, relying on thought-leadership content, expert Q&As, webinars, and editorial coverage to reach clinicians, scientists, hospitals, and global health researchers. It is led by CEO Julie Barrett O'Brien with a newly elected board (Jane Williams as Chair), headquartered in Woburn, MA, and serves customers across North America and South America (notably Paraguay).

Short descriptiontext

OpenBiome Foundation is a U.S. nonprofit that evolved from the first U.S. public stool bank into a research foundation advancing microbiome science through its biorepository, targeted grantmaking, and field-building programs for clinicians, scientists, hospitals, and global health researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMedford, United States
HQ citystring
Medford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics, stool banking services, biorepository access, research grantmaking, fecal microbiota transplantation
Industry4 codes
PRIMARYHLAAAFAE
Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAKAEAA
General Gastroenterology
NAICS code2 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Biological Products, (No Disgnostic Substances)2836
Product category
Microbiome Therapeutics Foundation
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Foundation/Grant Model
TypeProfessional Services
Description

As a nonprofit foundation, OpenBiome generates revenue through donations, grants, and charitable contributions rather than commercial product sales. They focus on advancing microbiome science through funding rather than direct revenue generation.

openbiome.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The OpenBiome Foundation is a nonprofit that advances microbiome science and expands patient access to microbiome therapies through targeted grantmaking, an open-access biorepository, field-building education, and policy advocacy. Originally the operator of the first U.S. public stool bank that delivered 72,000+ investigational FMT treatments to 1,300+ hospitals for recurrent C. difficile infections, the foundation now focuses on funding pioneering research, sharing biological resources, and championing sound health policy for C. diff patients following the FDA's 2025 decision to end enforcement discretion for stool banks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • FMT resolves 80-90% of recurrent C. difficile infections not responsive to antibiotic therapy
+1 more record
Product overview1 text field

OpenBiome Foundation operates as a nonprofit organization offering a portfolio of programs focused on accelerating microbiome science and expanding patient access to microbiome therapies. The core offerings include: (1) the OpenBiome Biorepository—an open-access biological resource repository of stool samples and associated data shared with researchers; (2) a Grant Making Program providing targeted funding for pioneering microbiome research; (3) Field Building initiatives including educational white papers, clinical webinars, and the OpenDialog newsletter featuring expert Q&As; and (4) advocacy and policy work to champion FMT access for C. difficile patients. The organization transitioned from its prior role as a stool bank providing investigational FMT treatments (over 72,000 treatments delivered to 1,300+ hospitals) to a foundation model focused on powering the next generation of discoveries through resource sharing and innovation support.

Product and service5 records
1Microbiome Research Grant Making Program
CategoryResearch Grantmaking
Description

Targeted grantmaking program providing financial investments and global collaborations to support pioneering microbiome research aimed at advancing scientific breakthroughs. Designed for microbiome researchers, principal investigators, and clinician-scientists seeking funding for high-impact microbiome studies.

2Open-Access Biorepository and Biological Resources
CategoryBiological Resources
Description

Open-access biological resource repository containing unparalleled stool samples and associated clinical data, made available to power the next generation of microbiome discoveries and scientific research. Targeted at microbiome researchers and clinicians worldwide.

3C. Diff Program — No Patient Left Behind
CategoryPatient Access and Policy Advocacy
Description

Advocacy and policy program designed to close critical gaps in C. difficile treatment access, champion sound health policy, and develop new models for hospital-based FMT programs. Targeted at healthcare systems, clinicians, and C. diff patient communities.

4Field Building and Clinical Education
CategoryField Building and Education
Description

Educational initiative comprising white papers, clinical webinars, research publications, expert Q&A content, and resources that equip clinicians, scientists, and healthcare systems with knowledge and tools to advance microbiome therapies. Targeted at clinicians, researchers, and healthcare systems.

5Hospital FMT Program Support and Know-How Sharing
CategoryImplementation and Advisory Services
Description

Advisory and know-how sharing service helping hospitals and healthcare systems establish their own IND-compliant FMT manufacturing capabilities after OpenBiome ceased commercial FMT distribution. Targeted at hospital leadership and clinical operations teams.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Partnership between 2022-2024 where UMN Microbiota Therapeutics Program served as manufacturer of FMT products for OpenBiome. Dr. Khoruts' program continues to work with OpenBiome Foundation to advocate for FDA reinstatement of enforcement discretion for severe/fulminant C. diff patients.

2Dr. Walter Sandoval - Paraguayan Gut Microbiome Project
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

OpenBiome funding enabled expansion of gut and vaginal microbiome studies, genotyping, and metabolomics research in Paraguay, including Indigenous communities. Facilitated connections with Poyet and Groussin Labs for international collaboration.

openbiome.org
3Poyet and Groussin Labs
Strategic tierMinorTypeStrategic or Co-development Partner
Description

International research collaboration connections facilitated through OpenBiome's networking efforts for Paraguayan microbiome research

openbiome.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

American Gastroenterological Association's FMT National Registry is a critical resource for advancing understanding of FMT safety and outcomes. OpenBiome strongly encourages all clinicians performing investigational FMT to participate in the registry.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Seres developed VOWST, the first FDA-approved oral fecal microbiota spore therapy for recurrent C. difficile. Directly comparable to OpenBiome as a microbiome-therapeutics company targeting the same disease with an FMT-derived approach.

TypeBroad incumbent
Description

Ferring commercializes Rebyota, the first FDA-approved live biotherapeutic for recurrent C. diff, originally developed by Rebiotix. A broader incumbent that overlaps with OpenBiome's FMT-for-C. diff mission but operates at global pharmaceutical scale.

TypeDirect peer
Description

Vedanta develops defined bacterial consortia for microbiome-based therapeutics, including programs targeting recurrent C. difficile. Directly comparable as a clinical-stage microbiome therapeutics peer advancing live biotherapeutics.

TypeRegional player
Description

European clinical-stage company developing microbiome-based therapies including FMT-derived products for C. diff and graft-versus-host disease. Comparable to OpenBiome's FMT and stool-banking focus but based in and primarily serving Europe.

TypeEmerging player
Description

Clinical-stage biotech developing microbiome-targeted therapies for serious diseases. Comparable to OpenBiome as a microbiome therapeutics player, though with a smaller, earlier-stage portfolio overlapping in FMT-adjacent indications.

6Second Genome
TypeEmerging player
Description

Microbiome drug discovery company developing therapeutics that modulate the microbiome. Comparable to OpenBiome in targeting microbiome-based interventions, though focused on small-molecule and biologic discovery rather than FMT delivery.

TypeOthers
Description

Operates the FMT National Registry, a key partner and data platform for FMT safety and outcomes that OpenBiome endorses. A professional society peer in advancing gastroenterology research, registries, and clinical guidelines.

TypeOthers
Description

Disease-focused nonprofit that drives research funding, advocacy, and patient access for cystic fibrosis. Comparable to OpenBiome Foundation as a health-focused grantmaker and advocacy organization, though operating at much larger scale.

TypeOthers
Description

Major philanthropic foundation funding medical research and clinical care, including translational science. Comparable to OpenBiome Foundation as a grantmaking peer focused on advancing biomedical research.

10OpenBiome Foundation / Wyss Institute partnership (Harvard)
TypeOthers
Description

Academic research institution that has historically collaborated on microbiome and engineering biology initiatives, with roots in OpenBiome's MIT heritage. A research-enabling peer in translational microbiome science, though not a direct competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OpenBiome

Microbiome Therapeutics Foundationopenbiome.org

OpenBiome Foundation is a U.S. nonprofit that evolved from the first U.S. public stool bank into a research foundation advancing microbiome science through its biorepository, targeted grantmaking, and field-building programs for clinicians, scientists, hospitals, and global health researchers.

What OpenBiome does

OpenBiome Foundation is a U.S. nonprofit organization, originally founded in 2012 as an MIT spinout, that operated the first public stool bank in the United States delivering investigational fecal microbiota transplantation (FMT) treatments for Clostridioides difficile (C. diff) infections. Over more than a decade it built standardized, cryopreserved FMT preparations and high-dose protocols for severe/fulminant disease, ultimately delivering 72,000+ investigational treatments to 1,300+ hospitals and clinics and contributing to the field that produced the first two FDA-approved live biotherapeutic drugs for C. diff. Following the FDA's decision to end enforcement discretion for stool banks, OpenBiome ceased direct FMT distribution in 2025 and reorganized as the OpenBiome Foundation on July 16, 2025.

Under the Foundation model, the organization no longer sells or distributes FMT products commercially. Its current offerings center on (1) the OpenBiome Biorepository—an open-access repository of stool samples and associated clinical data, (2) a targeted Grant Making Program funding pioneering microbiome research globally, (3) Field Building programs including white papers, clinical webinars, and the OpenDialog newsletter, and (4) advocacy for sound health policy and hospital-based FMT programs. Core technology assets include the proprietary donor screening and stool-banking protocols developed over the operational period and an IND-track manufacturing relationship with the University of Minnesota Microbiota Therapeutics Program (Dr. Alexander Khoruts).

The revenue model is foundation/grant-based: OpenBiome is funded through donations, grants, and charitable contributions rather than commercial sales, with disclosed historical capital limited to a $100K–$125K Y Combinator investment (Aug 2020) and small grants from the Draper Richards Kaplan Foundation (2022) and WPSS.bio (2020). Its go-to-market is community-led, relying on thought-leadership content, expert Q&As, webinars, and editorial coverage to reach clinicians, scientists, hospitals, and global health researchers. It is led by CEO Julie Barrett O'Brien with a newly elected board (Jane Williams as Chair), headquartered in Woburn, MA, and serves customers across North America and South America (notably Paraguay).

OpenBiome firmographics

Firmographics
Name
OpenBiome
Legal name
The OpenBiome Foundation
Website
https://openbiome.org
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
OpenBiome Foundation is a U.S. nonprofit that evolved from the first U.S. public stool bank into a research foundation advancing microbiome science through its biorepository, targeted grantmaking, and field-building programs for clinicians, scientists, hospitals, and global health researchers.
Ownership category
akta.pro rank

OpenBiome industry classification

Industry
Product category
Microbiome Therapeutics Foundation
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212)
SIC
Services-Misc Health & Allied Services, Nec (8090), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAE
Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAKAEAA
General Gastroenterology

Keywords

  • Microbiome therapeutics
  • Stool banking services
  • Biorepository access
  • Research grantmaking
  • Fecal microbiota transplantation

Where OpenBiome is headquartered

Location

Headquarters

HQ city
Medford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

OpenBiome business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Foundation/Grant Model: As a nonprofit foundation, OpenBiome generates revenue through donations, grants, and charitable contributions rather than commercial product sales. They focus on advancing microbiome science through funding rather than direct revenue generation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

OpenBiome product offering

Product offering

Core offering

The OpenBiome Foundation is a nonprofit that advances microbiome science and expands patient access to microbiome therapies through targeted grantmaking, an open-access biorepository, field-building education, and policy advocacy. Originally the operator of the first U.S. public stool bank that delivered 72,000+ investigational FMT treatments to 1,300+ hospitals for recurrent C. difficile infections, the foundation now focuses on funding pioneering research, sharing biological resources, and championing sound health policy for C. diff patients following the FDA's 2025 decision to end enforcement discretion for stool banks.

Product overview

OpenBiome Foundation operates as a nonprofit organization offering a portfolio of programs focused on accelerating microbiome science and expanding patient access to microbiome therapies. The core offerings include: (1) the OpenBiome Biorepository—an open-access biological resource repository of stool samples and associated data shared with researchers; (2) a Grant Making Program providing targeted funding for pioneering microbiome research; (3) Field Building initiatives including educational white papers, clinical webinars, and the OpenDialog newsletter featuring expert Q&As; and (4) advocacy and policy work to champion FMT access for C. difficile patients. The organization transitioned from its prior role as a stool bank providing investigational FMT treatments (over 72,000 treatments delivered to 1,300+ hospitals) to a foundation model focused on powering the next generation of discoveries through resource sharing and innovation support.

Differentiator

Problem solved

Functional benefit

Products and services

  • Microbiome Research Grant Making Program Targeted grantmaking program providing financial investments and global collaborations to support pioneering microbiome research aimed at advancing scientific breakthroughs. Designed for microbiome researchers, principal investigators, and clinician-scientists seeking funding for high-impact microbiome studies.
  • Open-Access Biorepository and Biological Resources Open-access biological resource repository containing unparalleled stool samples and associated clinical data, made available to power the next generation of microbiome discoveries and scientific research. Targeted at microbiome researchers and clinicians worldwide.
  • C. Diff Program — No Patient Left Behind Advocacy and policy program designed to close critical gaps in C. difficile treatment access, champion sound health policy, and develop new models for hospital-based FMT programs. Targeted at healthcare systems, clinicians, and C. diff patient communities.
  • Field Building and Clinical Education Educational initiative comprising white papers, clinical webinars, research publications, expert Q&A content, and resources that equip clinicians, scientists, and healthcare systems with knowledge and tools to advance microbiome therapies. Targeted at clinicians, researchers, and healthcare systems.
  • Hospital FMT Program Support and Know-How Sharing Advisory and know-how sharing service helping hospitals and healthcare systems establish their own IND-compliant FMT manufacturing capabilities after OpenBiome ceased commercial FMT distribution. Targeted at hospital leadership and clinical operations teams.

Quantifiable outcome

  • FMT resolves 80-90% of recurrent C. difficile infections not responsive to antibiotic therapy
  • +1 more outcomes

Companies that use OpenBiome

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

OpenBiome technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

OpenBiome partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, strategic and minor.

  • University of Minnesota Microbiota Therapeutics ProgramcoreStrategic or Co-development Partner · 1 January 2022Partnership between 2022-2024 where UMN Microbiota Therapeutics Program served as manufacturer of FMT products for OpenBiome. Dr. Khoruts' program continues to work with OpenBiome Foundation to advocate for FDA reinstatement of enforcement discretion for severe/fulminant C. diff patients.
  • Dr. Walter Sandoval - Paraguayan Gut Microbiome ProjectstrategicStrategic or Co-development PartnerOpenBiome funding enabled expansion of gut and vaginal microbiome studies, genotyping, and metabolomics research in Paraguay, including Indigenous communities. Facilitated connections with Poyet and Groussin Labs for international collaboration.
  • Poyet and Groussin LabsminorStrategic or Co-development PartnerInternational research collaboration connections facilitated through OpenBiome's networking efforts for Paraguayan microbiome research
  • AGA FMT National RegistrycoreStrategic or Co-development PartnerAmerican Gastroenterological Association's FMT National Registry is a critical resource for advancing understanding of FMT safety and outcomes. OpenBiome strongly encourages all clinicians performing investigational FMT to participate in the registry.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

OpenBiome competitors and assessment

Company assessment

Direct peers

  • Seres Therapeutics: Seres developed VOWST, the first FDA-approved oral fecal microbiota spore therapy for recurrent C. difficile. Directly comparable to OpenBiome as a microbiome-therapeutics company targeting the same disease with an FMT-derived approach.
  • Vedanta Biosciences: Vedanta develops defined bacterial consortia for microbiome-based therapeutics, including programs targeting recurrent C. difficile. Directly comparable as a clinical-stage microbiome therapeutics peer advancing live biotherapeutics.

Broad incumbents

  • Ferring Pharmaceuticals (Rebyota): Ferring commercializes Rebyota, the first FDA-approved live biotherapeutic for recurrent C. diff, originally developed by Rebiotix. A broader incumbent that overlaps with OpenBiome's FMT-for-C. diff mission but operates at global pharmaceutical scale.

Regional players

  • MaaT Pharma: European clinical-stage company developing microbiome-based therapies including FMT-derived products for C. diff and graft-versus-host disease. Comparable to OpenBiome's FMT and stool-banking focus but based in and primarily serving Europe.

Emerging players

  • Assembly Biosciences: Clinical-stage biotech developing microbiome-targeted therapies for serious diseases. Comparable to OpenBiome as a microbiome therapeutics player, though with a smaller, earlier-stage portfolio overlapping in FMT-adjacent indications.
  • Second Genome: Microbiome drug discovery company developing therapeutics that modulate the microbiome. Comparable to OpenBiome in targeting microbiome-based interventions, though focused on small-molecule and biologic discovery rather than FMT delivery.

Others

  • American Gastroenterological Association (AGA): Operates the FMT National Registry, a key partner and data platform for FMT safety and outcomes that OpenBiome endorses. A professional society peer in advancing gastroenterology research, registries, and clinical guidelines.
  • Cystic Fibrosis Foundation: Disease-focused nonprofit that drives research funding, advocacy, and patient access for cystic fibrosis. Comparable to OpenBiome Foundation as a health-focused grantmaker and advocacy organization, though operating at much larger scale.
  • Doris Duke Charitable Foundation: Major philanthropic foundation funding medical research and clinical care, including translational science. Comparable to OpenBiome Foundation as a grantmaking peer focused on advancing biomedical research.
  • OpenBiome Foundation / Wyss Institute partnership (Harvard): Academic research institution that has historically collaborated on microbiome and engineering biology initiatives, with roots in OpenBiome's MIT heritage. A research-enabling peer in translational microbiome science, though not a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

OpenBiome social profiles

Digital presence

OpenBiome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OpenBiome leadership team

Management profile

Number of profiles

Profiles5 records

OpenBiome funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OpenBiome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OpenBiome

What does OpenBiome do?

The OpenBiome Foundation is a nonprofit that advances microbiome science and expands patient access to microbiome therapies through targeted grantmaking, an open-access biorepository, field-building education, and policy advocacy. Originally the operator of the first U.S. public stool bank that delivered 72,000+ investigational FMT treatments to 1,300+ hospitals for recurrent C. difficile infections, the foundation now focuses on funding pioneering research, sharing biological resources, and championing sound health policy for C. diff patients following the FDA's 2025 decision to end enforcement discretion for stool banks.

Is OpenBiome a public or private company?

OpenBiome is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was OpenBiome founded?

OpenBiome was founded in 2012. It employs 11 to 50 people.

Where is OpenBiome based?

OpenBiome is headquartered in Medford, United States, in the North America region.

How does OpenBiome make money?

One revenue line is on record: foundation/Grant Model.

Who are OpenBiome's main competitors?

Direct peers on record are Seres Therapeutics and Vedanta Biosciences. Ferring Pharmaceuticals (Rebyota) is listed as a broad incumbent. MaaT Pharma is listed as a regional player. Emerging players are Assembly Biosciences and Second Genome. Others are American Gastroenterological Association (AGA), Cystic Fibrosis Foundation, Doris Duke Charitable Foundation and OpenBiome Foundation / Wyss Institute partnership (Harvard).

Does OpenBiome have an API?

No public API is recorded for OpenBiome.

What industry is OpenBiome in?

OpenBiome's product category is Microbiome Therapeutics Foundation. Its primary akta.pro industry code is HLAAAFAE, Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products, with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Harvard GazetteJulie Barrett O’Brien MC/MPA 2002: A career journey from coffee beans to public healthJulie Barrett O'Brien, CEO of OpenBiome, traces her career path from starting at Fidelity Investments and working at Dunkin Donuts corporate to becoming a leader in global health and microbiome science. A pivotal moment came when a journalist challenged her on Dunkin Donuts' stance on child labor in Guatemala, prompting her to study supply chain ethics and visit coffee farmers firsthand, which shifted her career toward the social impact sector. After completing her MC/MPA at Harvard Kennedy School, she spent a decade at Management Sciences for Health before leading OpenBiome, where she now focuses on expanding global microbiome research in developing countries and advocating for C. difficile treatments.NatureMicrobiome interventions for children raise the ethical stakesPhysicians are raising ethical concerns about unregulated microbiome interventions for children, including probiotics and faecal transplants. The global probiotic market is worth $87.7 billion, and the FDA will end enforcement discretion for OpenBiome's stool bank on 31 December. A large vaginal seeding trial is expected to finish in 2029.GlobeNewswireFecal transplant pills: Large-scale production beginsOpenBiome began large-scale production of FMT Capsule G3 pills for recurrent C. difficile infection, using a patent-pending Microbial Emulsion Matrix technology. A pilot study of 17 patients showed a 94% aggregate clinical cure rate after a second dose, with no adverse events. The pill aims to reduce procedural costs and risks compared to colonoscopy or enema delivery.GizmodoNeed a Fecal Transplant? There’s a Poop Bank For ThatOpenBiome, a nonprofit fecal bank founded by Princeton and MIT students, offers pre-screened human feces for fecal transplants. It has shipped 109 specimens to 12 clinics from three donors, with screening costs covered by a gift. The bank could become part of public health infrastructure, though synthetic alternatives like RePOOPulate are being explored.